Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Common Equity (2016 - 2025)

Historic Common Equity for Fortress Biotech (FBIO) over the last 13 years, with Q3 2025 value amounting to $65.2 million.

  • Fortress Biotech's Common Equity rose 61173.65% to $65.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.2 million, marking a year-over-year increase of 61173.65%. This contributed to the annual value of $22.7 million for FY2024, which is 85.61% up from last year.
  • Latest data reveals that Fortress Biotech reported Common Equity of $65.2 million as of Q3 2025, which was up 61173.65% from $43.9 million recorded in Q2 2025.
  • In the past 5 years, Fortress Biotech's Common Equity registered a high of $248.3 million during Q2 2021, and its lowest value of -$15.9 million during Q2 2023.
  • Over the past 5 years, Fortress Biotech's median Common Equity value was $43.9 million (recorded in 2025), while the average stood at $82.6 million.
  • In the last 5 years, Fortress Biotech's Common Equity tumbled by 11987.78% in 2024 and then soared by 92514.61% in 2025.
  • Quarter analysis of 5 years shows Fortress Biotech's Common Equity stood at $225.9 million in 2021, then plummeted by 77.85% to $50.0 million in 2022, then plummeted by 54.93% to $22.5 million in 2023, then increased by 0.86% to $22.7 million in 2024, then soared by 186.69% to $65.2 million in 2025.
  • Its Common Equity was $65.2 million in Q3 2025, compared to $43.9 million in Q2 2025 and $32.5 million in Q1 2025.